Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

Early dementia signs can resemble the normal cognitive changes of aging. But timely diagnosis can help people get the ...

Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...